PBM
Price
$0.69
Change
-$0.09 (-11.54%)
Updated
Jan 15, 11:57 AM (EDT)
Capitalization
4.97M
Intraday BUY SELL Signals
RLAY
Price
$7.67
Change
-$0.39 (-4.83%)
Updated
Jan 15, 12:05 PM (EDT)
Capitalization
1.4B
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PBM vs RLAY

Header iconPBM vs RLAY Comparison
Open Charts PBM vs RLAYBanner chart's image
Psyence Biomedical
Price$0.69
Change-$0.09 (-11.54%)
Volume$1.85K
Capitalization4.97M
Relay Therapeutics
Price$7.67
Change-$0.39 (-4.83%)
Volume$100
Capitalization1.4B
PBM vs RLAY Comparison Chart in %
PBM
Daily Signal:
Gain/Loss:
RLAY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
PBM vs. RLAY commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBM is a Hold and RLAY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (PBM: $0.78 vs. RLAY: $8.07)
Brand notoriety: PBM and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBM: 13% vs. RLAY: 54%
Market capitalization -- PBM: $4.97M vs. RLAY: $1.4B
PBM [@Biotechnology] is valued at $4.97M. RLAY’s [@Biotechnology] market capitalization is $1.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBM’s FA Score shows that 1 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).

  • PBM’s FA Score: 1 green, 4 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, RLAY is a better buy in the long-term than PBM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBM’s TA Score shows that 5 TA indicator(s) are bullish while RLAY’s TA Score has 4 bullish TA indicator(s).

  • PBM’s TA Score: 5 bullish, 3 bearish.
  • RLAY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PBM is a better buy in the short-term than RLAY.

Price Growth

PBM (@Biotechnology) experienced а -1.49% price change this week, while RLAY (@Biotechnology) price change was -1.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

RLAY is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RLAY($1.4B) has a higher market cap than PBM($4.97M). PBM YTD gains are higher at: 3.305 vs. RLAY (-4.610). PBM has higher annual earnings (EBITDA): -3.93M vs. RLAY (-322.8M). RLAY has more cash in the bank: 596M vs. PBM (7.15M). PBM has less debt than RLAY: PBM (2.5M) vs RLAY (33.3M). RLAY has higher revenues than PBM: RLAY (8.36M) vs PBM (0).
PBMRLAYPBM / RLAY
Capitalization4.97M1.4B0%
EBITDA-3.93M-322.8M1%
Gain YTD3.305-4.610-72%
P/E Ratio0.04N/A-
Revenue08.36M-
Total Cash7.15M596M1%
Total Debt2.5M33.3M8%
TECHNICAL ANALYSIS
Technical Analysis
PBMRLAY
RSI
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
PBM
Daily Signal:
Gain/Loss:
RLAY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FREAX14.480.10
+0.70%
Nuveen Real Estate Securities A
MEMGX44.260.19
+0.43%
MFS Emerging Markets Equity R3
RDWEX14.590.04
+0.27%
American Funds Dvlpg Wld Gr&Inc R4
GMEPX29.230.02
+0.07%
Goldman Sachs China Equity P
MSPRX24.04-0.34
-1.39%
Morgan Stanley Inst Advantage C

PBM and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBM has been loosely correlated with NEVPF. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if PBM jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBM
1D Price
Change %
PBM100%
-0.54%
NEVPF - PBM
54%
Loosely correlated
N/A
NRSN - PBM
36%
Loosely correlated
-1.83%
BCRX - PBM
27%
Poorly correlated
+0.44%
NMRA - PBM
25%
Poorly correlated
+0.47%
RLAY - PBM
25%
Poorly correlated
+1.64%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with NRIX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
+1.64%
NRIX - RLAY
52%
Loosely correlated
+0.58%
VIR - RLAY
52%
Loosely correlated
+8.08%
KURA - RLAY
51%
Loosely correlated
+1.63%
IMNM - RLAY
51%
Loosely correlated
+3.08%
BEAM - RLAY
50%
Loosely correlated
+2.49%
More